Does Aetna (CVS Health) Cover Tadalafil (Generic)?

How Aetna (CVS Health) Places Tadalafil on Its Formulary

Aetna places generic tadalafil on Tier 2 (preferred generic) or Tier 3 (non-preferred drug) depending on the specific plan year and whether the member is enrolled in a PPO, HMO, or high-deductible health plan. Tier placement directly determines cost-sharing before and after the deductible.

Tier 2 vs. Tier 3 Placement

On Tier 2, members typically pay a $10 to $45 copay per 30-day supply after meeting the deductible. On Tier 3, that copay climbs to $40 to $80 or more. The distinction matters because a single tier difference can shift annual out-of-pocket spending by $400 to $700 for a drug taken daily at the 5 mg dose used in BPH management.

Tadalafil 5 mg (daily dosing) and tadalafil 10 mg or 20 mg (as-needed dosing) may land on different tiers within the same plan. The FDA approved tadalafil 2.5 mg and 5 mg for once-daily use in both ED and BPH, and 10 mg and 20 mg for as-needed ED use. Prescribers should confirm which strength is on-formulary before writing the prescription.

Why the CVS Caremark PBM Matters

Aetna is owned by CVS Health, which also operates CVS Caremark as its pharmacy benefit manager. Caremark negotiates drug placement and rebates independently of Aetna's medical benefit. That means the formulary your patient sees through the Aetna member portal is actually managed by Caremark, and preferred-pharmacy networks (CVS retail, CVS Specialty, and CVS Mail Service) may offer lower cost-sharing than out-of-network pharmacies for the same generic tadalafil. Caremark's formulary management criteria influence which generics receive preferred placement each plan year.

Confirming Your Specific Plan's Formulary

Formularies change annually on January 1. The only authoritative way to confirm tadalafil's tier on a specific Aetna plan is to:

1. Log in to the Aetna member portal and use the drug-cost estimator tool.
2. Call the pharmacy benefit number on the back of the insurance card.
3. Ask the dispensing pharmacy to run a test claim before the prescription is submitted.

Prior Authorization Criteria for Tadalafil on Aetna

Prior authorization (PA) is required on the large majority of Aetna commercial plans for generic tadalafil. The PA difficulty is rated moderate-to-high, meaning documentation requirements are specific and incomplete submissions are frequently returned rather than approved or denied outright.

What Aetna Typically Requires

Aetna's PA criteria for tadalafil generally include all of the following:

• A confirmed diagnosis of erectile dysfunction (ICD-10: N52.x) or benign prostatic hyperplasia (ICD-10: N40.x) documented in the medical record.
• Prescriber attestation that the dose and frequency match the FDA-labeled indication. The FDA label specifies tadalafil 5 mg once daily for BPH or once-daily ED, and 10 mg or 20 mg as-needed for ED. (FDA prescribing information)
• Documentation that the member has no contraindications, particularly concurrent use of nitrates or soluble guanylate cyclase stimulators such as riociguat, which are absolute contraindications to all PDE5 inhibitors. This contraindication is class-wide and FDA-labeled.
• Evidence of a recent clinical evaluation. Aetna generally does not approve PA requests based on patient self-report alone.

Step Therapy and the Sildenafil-First Requirement

On many Aetna plans, tadalafil is subject to step therapy. This means the member must have tried and either failed or been contraindicated to at least one other PDE5 inhibitor, most commonly generic sildenafil (the generic form of Viagra), before tadalafil will be authorized.

Sildenafil is typically a Tier 1 or Tier 2 drug on Aetna formularies. The step-therapy requirement exists because sildenafil is often the lower-cost alternative. Clinically, both agents are PDE5 inhibitors with similar efficacy in randomized trials, though tadalafil's 36-hour half-life offers a distinct pharmacokinetic advantage for men who prefer less time pressure around dosing.

Step therapy can be waived if the prescriber documents a clinical reason tadalafil is specifically indicated. Valid reasons include:

• Documented adverse reaction to sildenafil (e.g., significant flushing, severe headache, or visual disturbance).
• Clinical preference for daily dosing to treat concurrent BPH and ED, since sildenafil is not FDA-approved for BPH and tadalafil is. The FDA granted tadalafil BPH approval in 2011.
• Patient taking a medication with a clinically significant CYP3A4 interaction that affects sildenafil more than tadalafil.

Authorization Duration and Renewals

When Aetna approves a tadalafil PA, the authorization typically runs 12 months. Renewal requires resubmission of documentation confirming the ongoing diagnosis and continued clinical need. Prescribers should calendar PA expiration dates and initiate renewals 30 to 45 days before expiration to avoid coverage gaps.

The Clinical Evidence Aetna Uses to Evaluate Tadalafil Requests

Insurance coverage decisions are informed by the clinical record. Understanding the trials behind tadalafil helps prescribers write stronger PA letters.

Key ED Trials

Brock et al. (2002, J Urol, N=1,112) was among the first large randomized controlled trials establishing tadalafil's efficacy in men with erectile dysfunction. The trial reported statistically significant improvements in IIEF scores at tadalafil 10 mg and 20 mg versus placebo, with response rates of 67% and 81% respectively at the 20 mg dose across 12 weeks. These data formed part of the FDA's basis for the 2003 approval.

A 2-year open-label extension study (Porst et al., 2006) confirmed that tadalafil's efficacy and tolerability were maintained with continuous daily use, a finding relevant to PA renewals. Long-term safety data showed no new safety signals beyond the established profile of headache, dyspepsia, back pain, and myalgia.

BPH-Specific Evidence

The FDA's 2011 approval for BPH was supported by four 12-week, placebo-controlled trials. Carson et al. (2014) meta-analyzed these trials and found that tadalafil 5 mg once daily reduced International Prostate Symptom Score (IPSS) by a mean of 3.8 points versus 1.7 points for placebo (P<0.001). For men with both ED and BPH, tadalafil 5 mg daily is the only PDE5 inhibitor with dual labeling, which is a strong clinical argument against step therapy to sildenafil in that population.

Cardiovascular Safety

The ACC/AHA 2018 guideline on the management of heart failure includes guidance on PDE5 inhibitor use and contraindications. Yafi et al. (2016) in Nature Reviews Urology summarized the cardiovascular safety profile of tadalafil: no increase in myocardial infarction or cardiovascular mortality in men without nitrate use. This cardiovascular safety context is sometimes requested by Aetna's PA reviewers when the prescriber note includes a cardiac diagnosis.

What to Do When Aetna Denies Tadalafil Coverage

Denial is not the end. Aetna's appeals process has two internal levels and an independent external review right guaranteed by the Affordable Care Act for most commercial plans.

Step 1, First-Level Internal Appeal

File within 180 days of the denial notice (sooner is better). Submit:

• The original denial letter.
• A peer-reviewed clinical summary explaining why tadalafil is medically necessary for this specific patient.
• Relevant trial citations. The Brock et al. Data (PubMed 12434054) and the BPH meta-analysis (PubMed 24848937) are appropriate references.
• Office notes documenting the diagnosis, prior treatment history, and any step-therapy attempts or contraindications.

Aetna must respond to a standard first-level internal appeal within 30 days for prospective requests or 60 days for retrospective requests under federal ERISA timelines. Federal appeals rights are summarized by CMS.

Step 2, Second-Level Internal Appeal or External Review

If the first-level appeal fails, the member may request a second-level internal review or proceed directly to an independent external review organization (IRO). External review is available under 45 CFR 147.136 for non-grandfathered plans and must be requested within four months of the final internal denial.

IRO decisions are binding on the insurer in most states. Win rates for external reviews vary by indication but average 39% to 45% in favor of the patient across all drug appeals, according to CMS external review data.

Expedited Appeals for Urgent Need

If the denial involves a drug already in use and a coverage gap would cause serious harm, an expedited internal appeal must be resolved within 72 hours under federal rules. The ACA mandates expedited review timelines for urgent cases.

The HealthRX PA-to-Appeal Decision Framework for Tadalafil on Aetna:

1. Confirm formulary tier and PA requirement before writing the prescription.
2. Submit the PA with complete ICD-10 coding, trial documentation of ED or BPH, and a step-therapy waiver rationale if applicable.
3. If denied, file a first-level internal appeal within 30 days (not 180) to keep the process fast.
4. If the first-level appeal is denied, escalate directly to external review rather than a second internal review, since IRO decisions are binding.
5. While the appeal is pending, use the cash-pay option (approximately $80 per month) or a GoodRx coupon at a CVS pharmacy to avoid a treatment gap.

Out-of-Pocket Costs: Insured vs. Cash-Pay vs. Telehealth

Understanding the cost structure helps patients make an informed decision about whether to pursue coverage or simply pay out of pocket.

Insured Cost Under Aetna

With active coverage and no deductible remaining:

• Tier 2 copay: approximately $15 to $45 per 30-day supply.
• Tier 3 copay: approximately $40 to $80 per 30-day supply.

Before the deductible is met, the member pays the plan's contracted rate, which for generic tadalafil is typically $30 to $60 per month depending on the pharmacy network.

Cash-Pay and Discount Programs

Generic tadalafil's manufacturer list price is approximately $450 per month. The cash-pay average at major pharmacies (CVS, Walgreens, Walmart) is approximately $80 per month without any discount program. With GoodRx or a similar coupon, the price drops to $15 to $40 per month for a 30-day supply of tadalafil 5 mg or 20 mg at many locations.

The FDA's generic drug approval database lists multiple approved manufacturers of generic tadalafil, which contributes to competitive cash pricing.

Manufacturer Savings Cards and Aetna

Manufacturer savings cards for brand-name Cialis are not applicable to generic tadalafil. Generic manufacturers occasionally offer discount programs, but these are separate from the brand copay cards. Critically, federal law prohibits the use of any manufacturer coupon or assistance program for patients enrolled in a federal health care program (Medicare Part D, Medicaid, TRICARE). This prohibition is codified under the federal anti-kickback statute. Aetna commercial plan members are generally eligible to use third-party discount programs, but the discount cannot be applied to the insurance deductible in most cases.

Telehealth and Compounded Alternatives

Some telehealth platforms prescribe compounded tadalafil at lower prices. Compounded tadalafil is not FDA-approved and is not covered by Aetna. The FDA has published guidance on compounded drug risks, noting that compounded drugs lack the manufacturing oversight of approved generics. For patients who need cost-effective treatment while a PA appeal is pending, FDA-approved generic tadalafil purchased with a GoodRx coupon at cash pay is the lower-risk option compared to compounded alternatives.

Tadalafil for BPH vs. ED: Does the Indication Affect Aetna Coverage?

The clinical indication significantly affects how Aetna processes the PA. BPH and ED are separate FDA-approved indications with separate ICD-10 codes, and some plans treat them differently at the formulary level.

BPH Coverage Pathway

For BPH (ICD-10: N40.1, benign prostatic hyperplasia with lower urinary tract symptoms), tadalafil 5 mg daily is a guideline-supported treatment. The American Urological Association (AUA) 2021 guideline on benign prostatic hyperplasia lists PDE5 inhibitors as an option for men with BPH and concurrent ED. That guideline language strengthens the clinical argument for tadalafil over alpha-blockers alone in the right patient population.

BPH is considered a medical condition rather than a lifestyle indication by most Aetna plans, which means the step-therapy requirements may be less stringent than for ED alone. A prescriber note that specifically uses BPH language and cites LUTS severity (e.g., IPSS score of 15 or higher) is more likely to succeed in PA review.

ED Coverage Pathway

For ED alone (ICD-10: N52.x), some Aetna plans apply a lifestyle-drug exclusion, particularly self-insured employer plans that have opted out of ED drug coverage entirely. The PDE5 inhibitor exclusion is a common employer plan design choice and is legally permissible under ERISA. If the plan document contains explicit language excluding drugs for sexual dysfunction, no appeal will overturn that exclusion because it is a benefit design decision rather than a medical necessity determination.

Before investing time in a PA or appeal for an ED-only indication, the prescriber should verify whether the plan document excludes ED drugs. That information is in the Summary Plan Description (SPD) or Evidence of Coverage document available from the employer's HR department or the Aetna member portal.

Dual-Indication Strategy

For men with both ED and BPH, prescribers should code both diagnoses on the PA request. A claim submitted with only N52.x may be denied under an ED exclusion, while the same claim submitted with N40.1 and N52.x may be approved under the BPH benefit. This is not a workaround; it is accurate coding when both conditions are clinically documented in the medical record. Accurate ICD-10 coding in PA submissions is discussed in the AUA's coding and reimbursement guidance.

Writing a Strong PA Letter for Aetna: Key Elements

The PA letter is the single document that most often determines approval or denial. Most denials result from incomplete letters rather than unmet criteria.

Required Components

A PA letter for generic tadalafil on Aetna should include:

• Patient name, date of birth, Aetna member ID.
• Prescriber NPI, DEA (if applicable), contact information for peer-to-peer review.
• Specific diagnosis with ICD-10 code and date of diagnosis.
• Symptom severity: IIEF score for ED (below 21 indicates dysfunction), IPSS score for BPH (8 or above indicates moderate-to-severe symptoms).
• Requested drug, dose, frequency, and supply duration.
• Prior treatment history, including names and doses of any PDE5 inhibitors previously tried.
• Reason for tadalafil specifically if sildenafil step therapy has not been completed (adverse event, contraindication, or BPH indication).
• One or two supporting citations. The Brock et al. Trial (PubMed 12434054) and the FDA prescribing information are the two most directly relevant.

Peer-to-Peer Review

If the initial PA is denied, requesting a peer-to-peer review (a direct phone call between the prescriber and Aetna's reviewing physician) resolves many moderate-difficulty cases without a formal appeal. Peer-to-peer review must be requested within the timeframe specified in the denial letter, typically 10 to 14 business days. Peer-to-peer review processes are described in Aetna's provider manual.

Special Populations and Coverage Considerations

Medicare Part D and Aetna Medicare Plans

Aetna also sells Medicare Part D standalone prescription drug plans and Medicare Advantage (MA-PD) plans. Under Medicare Part D, drugs used primarily for sexual dysfunction are excluded from coverage by statute (Social Security Act Section 1860D-2(e)(2)(A)). This means tadalafil for ED is not covered under any Aetna Medicare Part D or MA-PD plan, regardless of tier or PA.

Tadalafil for BPH may be covered under some Medicare Advantage plans as a medically necessary drug when the primary indication is LUTS rather than sexual function. The plan's formulary and exceptions process governs this.

Men Under 40

Erectile dysfunction in men under 40 has a documented prevalence of approximately 8% based on Capogrosso et al. (2013, J Sex Med, N=439). Aetna's PA criteria do not typically include an age floor for tadalafil coverage, but reviewers may request additional workup (e.g., testosterone level, metabolic panel) before approving treatment in younger men, particularly when psychogenic rather than organic ED is suspected.

Diabetes and Cardiovascular Comorbidities

Men with type 2 diabetes have a 2- to 3-fold higher rate of ED than the general population. Malavige and Levy (2009, J Sex Med) reported ED prevalence of 52% to 75% in men with longstanding diabetes. Including the diabetes diagnosis (ICD-10: E11.x) in the PA request along with documented peripheral neuropathy or vascular disease strengthens the medical necessity argument and signals organic rather than psychogenic etiology.